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tion and improvement in physiologic status
may be achieved to improve survival follow-
ing the transplant.3
A possible scoring system for better se-
lection of patient criteria is sought. In this
context the Acute Physiology and Chronic
Health Evaluation II (APACHE II) scoring
system, a multiparameter, physiology-based
predictor of outcome, might be helpful. It can
aid in both selection and timing of LVAD
implantation, particularly in patients not
meeting normal hemodynamic criteria for
LVAD usage.4
Development of right ventricular failure
often causes poor results in patients with
LVADs. It is important to take into consid-
eration the predictive factors including the
need for circulatory support, female gender,
and nonischemic etiology, along with the he-
modynamic alterations including low pulmo-
nary artery pressure and low right ventricle
stroke work index, that might indicate poor
right ventricular outcome.5 Careful observa-
tion of the above would assist both in pa-
tient selection and clinical handling of
isolated LVAD implants.
Omer Ashraf, MBBS
Aga Khan University
Karachi, Pakistan
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Reply to the Editor:
We thank Dr Ashraf for his comments on
our recent article concerning the use of left
ventricular assist devices (LVADs) in pa-
tients with chronic congestive heart fail-
ure.1 His letter invites us to discuss several
important points.
First, to clarify the device type used pre-
dominantly at our center and used exclu-
sively in our study, we favor the HeartMate
XVE (single-lead vented electric) LVAD
(Thoratec Corp, Pleasanton, CA) for its rela-
tive ease of implantation, durability, and lack
of need for systemic anticoagulation. Our
long-term experience with this device has
paralleled an evolution in design, resulting in
improved bridge-to-transplant and posttrans-
plant survival rates.2
Next, we could not agree more with Dr
Ashraf’s observation that the timing of
transplantation following LVAD insertion
plays a critical role in determining survival.
Our own unpublished data show near nor-
malization of blood urea nitrogen, creatinine,
and liver function values at approximately 3
months of support time, bolstering the con-
cept of enhanced end-organ perfusion by the
LVAD. Moreover, the smooth transition to
cardiac rehabilitation and nutritional optimi-
zation throughout the recovery period are of
critical importance.
Although we do not employ the Acute
Physiology and Chronic Health Evaluation
II (APACHE II) scoring system ourselves,
we use similar clinical and laboratory-
based parameters to select LVAD candi-
dates. All patients referred for LVAD are
generally refractory to maximal medical ther-
apy, which often includes the use of intrave-
nous inotropes, vasopressors, and intra-aortic
balloon pumps. Exclusion is therefore done
on the basis of such factors as ventilatory
status, elevated pulmonary pressures, and pro-
longed prothrombin time.
Despite the physiologic benefits of LVADs,
even as they apply to the right ventricle,
right heart failure (RHF) occurs in approx-
imately 15% to 20% of patients postoper-
atively.3,4 Multiple studies have sought to
identify demographic and hemodynamic risk
factors predictive of the development of
RHF, but in practice, these parameters often
exhibit variable outcomes. Although the best
treatment for RHF is avoidance, when it does
become manifest, a low threshold should be
maintained to promptly start inotropic (ie,
milrinone) and pulmonary vasodilator (ie, ni-
tric oxide) therapy, with a right ventricular
assist device close at hand.
Nicholas C. Dang, MD
Yoshifumi Naka, MD, PhD
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Apoptosis in ischemic spinal cord
injury
To the Editor:
We read the article of Suzuki and associ-
ates1 titled “Experimental study on the pro-
tective effects of edaravone against isch-
emic spinal cord injury” with great interest.
They studied the effect of a free radical scav-
enger named “edaravone” in a rabbit model
of transient aortic occlusion and claimed its
protective effect on the ischemia-reperfusion
injury of spinal cord by suppressing the level
of reactive oxygen species (ROS). We con-
gratulate Suzuki and associates for their ex-
cellent study. We think that the introduction
of microdialysis method to determine the
production of ROS in the neuronal tissue
after transient ischemia for the first time in
the literature by the authors is a great con-
tribution to our current knowledge.
Recently, data has accumulated that
programmed cell death or apoptosis of mo-
tor neurons in spinal cord after transient
ischemia is an outstanding mechanism of
postoperative paraplegia or paraparesis.2,3
The neuronal injury following transient aortic
occlusion occurs in 2 phases, namely, early
and delayed. Ischemic insult in spinal cord
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activates apoptosis by plasma membrane
death receptor pathway, activation of caspase
enzymes, and release of cytochrome c from
mitochondria. Although blood flow to the
spinal cord is restored during reperfusion,
the motor neurons that seem to survive
ischemic insult may undergo delayed selec-
tive death, particularly 7 days after the pro-
cedure.4 Despite that the etiology of delayed
selective neuronal death has been proposed to
be the activation of Akt protein, Grp78, and
caspase 12 proteins, further studies should be
warranted. In the present study, the authors
claimed the protective effect of edaravone
on spinal cord injury according to the his-
tologic examination and levels of ROS.
However, it is known that these neurons
might be apoptotic despite the normal cel-
lular architecture seen on the hematoxylin
and eosin (H & E) staining. The authors did
not focus on apoptotic mechanisms and dem-
onstrated only necrotic (ghost) neurons with
H & E staining without considering the
neurons undergoing apoptosis. In this re-
gard, we believe that addition of the neu-
ronal apoptosis would increase the statisti-
cal power of this study.
Koray AK
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Selim Isbir
Marmara University Faculty of Medicine
Department of Cardiovascular Surgery
Istanbul, Turkey
References
1. Suzuki K, Kazui T, Terada H, Umemura K,
Ikeda Y, Bashar AH, Yamashita K, et al. Ex-
perimental study on the protective effects of
edaravone against ischemic spinal cord injury.
J Thorac Cardiovasc Surg. 2005;130:1586-92.
2. Isbir CS, Ak K, Kurtkaya O, Zeybek U, Ak-
gun S, Scheitauer BW, Sav A, et al. Ischemic
preconditioning and nicotinamide in spinal
cord protection in an experimental model of
transient aortic occlusion. Eur J Cardiotho-
rac Surg. 2003;23:1028-33.
3. Sakurai M, Takahashi G, Abe K, Horinouchi
T, Itoyama Y, Tabayashi K. Endoplasmic re-
ticulum stress induced in motor neurons by
transient spinal cord ischemia in rabbits.
J Thorac Cardiovasc Surg. 2005;130:640-5.
4. Sakurai M, Nagata T, Abe K, Horinouchi T,
Itoyama Y, Tabayashi K. Survival and death-
promoting events after transient spinal cord
ischemia in rabbits: induction of Akt and
caspase3 in motor neurons. J Thorac Cardio-
vasc Surg. 2003;125:370-7.
doi:10.1016/j.jtcvs.2005.12.056
Reply to the Editor:
We thank Dr AK for his insightful com-
ments on our recently published article.
Paraplegia or paraparesis occurring in the
late postoperative period is well described
in the literature. The mechanism of this de-
layed spinal deficit is presumed to be related
with apoptosis. Sakurai and colleagues1 eval-
uated the relationship between delayed para-
plegia and apoptosis using immunohistochem-
ical techniques. In their experimental study,
the transient spinal ischemic time was 15
minutes. Two days after the reperfusion, the
mean Johnson score was 4.9  0.894, and
3 of the 5 rabbits had normal hind-limb
function. In our study,2 we applied a spinal
ischemic time of 30 minutes. Two days
after the reperfusion, all rabbits in the con-
trol group were completely paraplegic with
a Johnson score of 0. The focus of our
investigation was to assess whether pro-
phylactic administration of edaravone could
suppress necrosis and not apoptosis of the
spinal cord. Consequently, a longer spinal
ischemic time was employed and only
hematoxylin-eosin staining was used for
histopathologic evaluation. As suggested by
AK, motor neurons that appear intact on he-
matoxylin and eosin staining as a result of the
prophylactic administration of edaravone
might suffer delayed apoptosis-related injury.
Because we did not use any marker for
apoptosis in our study, we are not in a
position to comment on this. However, we
agree with Dr AK that further studies need
to be undertaken to clarify this issue. We
are indeed planning to embark on a protocol
that involves the use of markers of apopto-
sis in a model of shorter spinal ischemic
time and longer duration of observation.
Kazuchika Suzuki, MD
Teruhisa Kazui, MD, PhD
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Surgical treatment for congestive
heart failure with autologous adult
stem cell transplantation
To the Editor:
Patel and colleagues1 have provided further
evidence of the benefit of autologous stem
cell transplantation in patients with isch-
emic cardiomyopathy. However, even if, in
the past years, observational studies and
some randomized controlled trials have es-
tablished that autologous stem cell transplan-
tation has led to significant improvement in
myocardial infarction and congestive heart
failure, this study unfortunately has not spe-
cifically addressed several clinically relevant
questions: What dose of CD34 cells for
stem cell therapy in this area should we use?
Furthermore, what is the best cell type and
the best cell dose for each cell type?
In recent studies, doses of CD34 cells
ranging from 106 to 108 have been used;
however, if the optimum dose of CD34
cells needed is proven to be much less than
106, procedures involved in collecting suf-
ficient amounts for therapeutic use can be
less time-consuming and thus potentially
cost-saving. Furthermore, the expression of
CD34 surface antigen characterizes a het-
erogeneous population of cells including
hematopoietic progenitor cells, endothelial
progenitor cells, mature endothelial cells,
and tissue-committed stem cells as recently
reported.2 It is still not clear whether the
beneficial effect of these cells in regenera-
tion can be explained by the transdifferen-
tiation of hematopoietic stem cells, the
paracrine secretion of angiopoietic factors
from bone marrow-derived stem cells,3 or the
presence of tissue-committed stem cells for
myocardium or endothelium. We believe that
there is a pressing need to standardize thera-
peutic protocols to allow tailor-made thera-
pies for these patients.
Vincenzo Pitini, MD
Giuseppe Altavilla, MD
Carmela Arrigo, MD
Department of Medical Oncology and Bone
Marrow Transplantation
University of Messina, Italy
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